Equities analysts expect Global Blood Therapeutics Inc (NASDAQ:GBT) to post $1.05 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Global Blood Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $2.00 million. The company is scheduled to report its next quarterly earnings report on Wednesday, February 26th.
According to Zacks, analysts expect that Global Blood Therapeutics will report full-year sales of $940,000.00 for the current year, with estimates ranging from $200,000.00 to $2.00 million. For the next financial year, analysts forecast that the company will report sales of $41.48 million, with estimates ranging from $21.10 million to $68.99 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Global Blood Therapeutics.
Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same quarter last year, the business earned ($0.83) earnings per share.
A number of equities research analysts have commented on GBT shares. Nomura raised their target price on Global Blood Therapeutics from $109.00 to $112.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $98.00 price target (down from $110.00) on shares of Global Blood Therapeutics in a research note on Monday, November 25th. ValuEngine cut shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. William Blair reiterated a “buy” rating on shares of Global Blood Therapeutics in a report on Tuesday, October 8th. Finally, SunTrust Banks raised their price objective on shares of Global Blood Therapeutics to $110.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $91.44.
Shares of GBT stock opened at $76.15 on Friday. The business’s fifty day moving average price is $54.14 and its 200 day moving average price is $53.59. The firm has a market capitalization of $4.01 billion, a PE ratio of -22.33 and a beta of 1.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.95 and a quick ratio of 14.95. Global Blood Therapeutics has a 1-year low of $34.92 and a 1-year high of $77.95.
In related news, insider De Dominicis Robert 490,012 shares of the stock in a transaction dated Tuesday, October 22nd. Also, insider Lesley Ann Calhoun sold 2,765 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total transaction of $150,305.40. Following the transaction, the insider now directly owns 887 shares of the company’s stock, valued at $48,217.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,616 shares of company stock valued at $2,096,540. Company insiders own 4.30% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co NY grew its holdings in Global Blood Therapeutics by 6.5% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 17,963 shares of the company’s stock valued at $872,000 after buying an additional 1,090 shares during the last quarter. Man Group plc purchased a new stake in shares of Global Blood Therapeutics in the third quarter valued at $2,671,000. Point72 Asset Management L.P. purchased a new stake in shares of Global Blood Therapeutics in the third quarter valued at $34,343,000. California State Teachers Retirement System boosted its stake in shares of Global Blood Therapeutics by 7.7% during the third quarter. California State Teachers Retirement System now owns 90,269 shares of the company’s stock valued at $4,380,000 after acquiring an additional 6,446 shares during the last quarter. Finally, Pictet Asset Management Ltd. boosted its stake in shares of Global Blood Therapeutics by 22.9% during the third quarter. Pictet Asset Management Ltd. now owns 539,510 shares of the company’s stock valued at $26,177,000 after acquiring an additional 100,653 shares during the last quarter. Hedge funds and other institutional investors own 98.78% of the company’s stock.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
See Also: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.